Skip to main content

Veppanu

VEPPANU can offer more time without disease progression

Explore the results

In a clinical study, VEPPANU helped people live longer without their cancer growing or spreading, also known as progression-free survival (PFS), for 2.4x longer than fulvestrant

Trial results graphic showing median progression-free survival of 5 months with VEPPANU (vepdegestrant) versus 2.1 months with fulvestrant

Median PFS of 5 months for VEPPANU vs 2.1 months for fulvestrant

VEPPANU significantly reduced the risk of progression or death by 43% when compared to fulvestrant

Trial results graphic illustrating about 5 times as many patients had tumors shrink with VEPPANU (vepdegestrant) versus fulvestrant. Objective response rate is 19% with VEPPANU and 4% with fulvestrant.
~ 5 x

as many patients had tumors shrink with VEPPANU vs fulvestrant

Objective Response Rate:

19% with VEPPANU
4% with fulvestrant

Patient-reported quality of life was
studied in the VEPPANU clinical trial

Patient-reported quality of life was studied in the VEPPANU clinical trial

Median time until overall quality of life worsened
Trial participants were given a standardized 30-question survey that evaluated measures of quality of life during the trial, including overall health, symptoms (fatigue, pain, nausea/vomiting, shortness of breath, insomnia, appetite loss, constipation, diarrhea), and functioning (physical, role, emotional, mental, social).
  • The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), used in the VEPPANU clinical study, is not all inclusive and does not include adequate assessment of all expected treatment-related symptoms. Total time to disease deterioration may be affected by events not related to disease or treatment
  • Measurements were defined by deterioration, or worsening, which was considered to be a clinically meaningful reduction in quality of life, as measured by the EORTC QLQ-C30. Patients gave a numeric score to each question
  • The study was not specifically designed to reliably detect differences between treatments in these patient-reported results

Every patient is different, and your results may vary. Interpret these findings carefully; treatment, cancer, or other factors may have affected the results, and the assessments may not have accounted for all treatment-related symptoms. 



Talk with your doctor about what these findings may mean for you.

Two women preparing food together in a kitchen

Actor portrayal.

How VEPPANU was studied

VEPPANU was studied in 270 adults living with ER+/HER2-, ESR1-mutated (ESR1m) metastatic breast cancer (mBC) .
All participants' disease progressed on endocrine-based therapy , including with a CDK4/6i.

Most side effects of VEPPANU were mild to moderate in nature. See what you can expect.

View safety profile

CDK4/6i=cyclin-dependent kinase 4/6 inhibitor; ER+=estrogen receptor-positive; ESR1=estrogen receptor 1; HER2-=human epidermal growth factor receptor 2-negative.

VEP_BC-26083